Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis.

Date publication

décembre 2022

Journal

NEJM evidence

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MINELLO Anne

Tous les auteurs :
Plessier A, Goria O, Cervoni JP, Ollivier I, Bureau C, Poujol-Robert A, Minello A, Houssel-Debry P, Rautou PE, Payancé A, Scoazec G, Bruno O, Corbic M, Durand F, Vilgrain V, Paradis V, Boudaoud L, de Raucourt E, Roy C, Gault N, Valla D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38319842

Résumé

Rivaroxaban Prophylaxis in Noncirrhotic PVTThis trial assessed the effects of rivaroxaban on the risk of venous thromboembolism and portal hypertension-related bleeding in patients with noncirrhotic chronic portal vein thrombosis without major risk factors for thrombosis. Daily rivaroxaban use reduced the incidence of venous thromboembolism and did not increase major bleeding events.

Référence

NEJM Evid. 2022 12;1(12):EVIDoa2200104